ArticleAmerican journal of translational research2021
Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: a large population-based study.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Development and validation of an interpretable machine learning-based predictive model for breast cancer bone metastasis.Frontiers in oncology · 2026Article
- Targeting Netrin-1 Mediates the Suppression of Osteolytic Bone Metastasis in Breast Cancer by Ugonin L.International journal of biological sciences · 2026Article
- Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Identification of the optimal candidates to benefit from surgery and chemotherapy among elderly female breast cancer patients with bone metastases.Scientific reports · 2025Article
- Development and validation of a nomogram for predicting bone metastasis in breast cancer: a retrospective study.Frontiers in surgery · 2025Article
- Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis.Heliyon · 2024Review
- Development and validation of an artificial intelligence model for predicting de novo distant bone metastasis in breast cancer: a dual-center study.BMC women's health · 2024Article
- Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.Scientific reports · 2023Article
- Review
- Development and Validation of Prognostic Nomogram for Elderly Breast Cancer: A Large-Cohort Retrospective Study.International journal of general medicine · 2022Article
- Bone metastasis risk and prognosis assessment models for kidney cancer based on machine learning.Frontiers in public health · 2022Article
- Machine learning predicts the prognosis of breast cancer patients with initial bone metastases.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone is the most common metastatic site for breast cancer, and patients' condition will deteriorate when it occurs.
methodsWe performed a retrospective analysis on 6482 breast cancer patients with bone metastases (BCBM), who were selected from the Surveillance, Epidemiology, and End Result (SEER) 18 registry database. The optimal age cut-points were generated by using the X-tile software. By using Cox regression, we selected independent prognostic factors from 21 variables, and plotted a visual nomogram to predict the probability of surviving to the median survival time. We also diagrammed a competing risk nomogram on the basis of competitive risk model.
resultsCompared with other three common metastatic sites, the incidence of bone metastasis was the highest for patients with breast cancer. The incidence of BCBM peaked around the age of 60, and a large majority of patients were between the ages of 50 and 70. The survival rate decreased with age, and the median survival time was about 19 months. Factors of age, race, marital status, grade, human epidermal growth factor receptor-2 (HER2) receptor, hormone receptor, concurrent brain metastasis, concurrent liver metastasis, concurrent lung metastasis, surgery and chemotherapy are strongly related to the prognosis of patients with BCBM. It was revealed that the C-index of the nomogram was 0.72 and the calibration curves showed good agreement between the nomogram prediction and actual observation.
conclusionOur practical nomograms provide a visual and user-friendly tool in the risk evaluation and prognostic prediction for breast cancer patients with bone metastases.
Indexed as
Identifiers
34650694PMC8507056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.